Meeting
2016 ASCO Annual Meeting
Comparative effectiveness of FOLFIRINOX or nab-paclitaxel plus gemcitabine in locally advanced or metastatic pancreatic cancer: A population-based analysis.
Authors
Ying Wang
University of British Columbia, Vancouver, BC, Canada
Ying Wang , Leo Chen , Pierre Camateros , Sharlene Gill , Daniel John Renouf , Winson Y. Cheung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research and Quality of Care
Track
Health Services Research and Quality of Care
Sub Track
Outcomes
Citation
J Clin Oncol 34, 2016 (suppl; abstr 6561)
DOI
10.1200/JCO.2016.34.15_suppl.6561
Abstract #
6561
Poster Bd #
48
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Efficacy of nab-paclitaxel plus gemcitabine (AG) vs. FOLFIRINOX as first line chemotherapy for metastatic pancreatic cancer (mPC): Real world experiences.
First Author: Inhwang Hwang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Depth of response in patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory subgroup analysis of JCOG1407.
First Author: Taro Shibuki
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of sequential perioperative FOLFIRNOX plus gemcitabine nab-paclitaxel for resected pancreatic and periampullary cancers.
First Author: Putao Cen
Poster
2021 ASCO Annual Meeting
Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).
First Author: Masato Ozaka